Creatine for Depressed Male and Female Methamphetamine Users
Status: | Recruiting |
---|---|
Conditions: | Anxiety, Anxiety, Depression, Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - 59 |
Updated: | 4/21/2016 |
Start Date: | November 2015 |
End Date: | May 2017 |
Contact: | Tracy Hellem, PhD |
Email: | tracy.hellem1@montana.edu |
Phone: | 406 243 2110 |
An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users
- Assess the antidepressant/anxiolytic effect of creatine in male and female
methamphetamine users
- Assess creatine's effect on methamphetamine use
- Assess the safety of creatine in male methamphetamine users with depression
methamphetamine users
- Assess creatine's effect on methamphetamine use
- Assess the safety of creatine in male methamphetamine users with depression
Inclusion Criteria:
- Current primary diagnosis of methamphetamine dependence or abuse, with
methamphetamine preferred drug of abuse
- Current diagnosis of major depressive disorder (primary or substance-induced)
- Current diagnosis of an anxiety disorder (primary or substance-induced)
- Current Hamilton Depression Rating scale score > or = to 16
- Current Hamilton Anxiety Scale score > = to 18
- If taking a psychotropic medication for depressed or anxious mood, regimen must be
stable for > = to 4 weeks prior to creatine treatment initiation
Exclusion Criteria:
- Persons unable to provide adequate informed consent
- Persons who are at clinically significant suicidal or homicidal risk
- Primary substance-related diagnosis other than methamphetamine dependence or abuse
- Positive pregnancy test (females only)
- History of renal disease
- Clinically significant medical or neurological illness identified by history,
physical exam and laboratory testing
- History of hypersensitivity reaction to creatine
We found this trial at
1
site
Missoula, Montana 59812
Principal Investigator: Tracy Hellem, PhD
Phone: 406-243-2110
Click here to add this to my saved trials